<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01782118</url>
  </required_header>
  <id_info>
    <org_study_id>1/2013</org_study_id>
    <nct_id>NCT01782118</nct_id>
  </id_info>
  <brief_title>LGG for Prevention of Infectious Complications During PPI Treatment in Children</brief_title>
  <official_title>Effectiveness of Lactobacillus GG in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children With Gastroesophageal Reflux Disease Treated With Proton Pump Inhibitors: Randomized Double - Blind Placebo, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Proton pump inhibitors (PPI) are effective for treating gastroesophageal reflux
      disease (GERD). However, they may be associated with an increased risk of gastrointestinal
      and respiratory tract infections.

      Aim: To determine if Lactobacillus GG (LGG) is an effective adjunct to PPI for reducing the
      risk of gastrointestinal and respiratory tract infections in children with GERD.

      Study design: Randomized, double-blind, placebo controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with GERD treated with PPI will be randomly assigned to receive LGG in dose of 10(9)
      Colony Forming Units (CFU) twice daily for 6 weeks or a comparable placebo twice daily for 6
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory tract infections</measure>
    <time_frame>up to 3 months after termination of intervention</time_frame>
    <description>Number of upper and lower respiratory tract infections during intervention plus 3 months after termination of the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal tract infections</measure>
    <time_frame>up to 3 months after termination of intervention</time_frame>
    <description>Number of gastrointestinal tract infections during during intervention plus 3 months after termination of the intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of pneumonias</measure>
    <time_frame>up to 3 months after termination of intervention</time_frame>
    <description>during intervention plus 3 months after termination of the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 3 months after termination of intervention</time_frame>
    <description>Number and character of adverse events during intervention plus 3 months after termination of the intervention.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>serum level of 25OHD</measure>
    <time_frame>at 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum level of ferritin</measure>
    <time_frame>at 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total iron binding capacity</measure>
    <time_frame>at 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum level of ferrum</measure>
    <time_frame>at 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>fecal calprotectin</measure>
    <time_frame>at 6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <condition>Gastrointestinal Infections</condition>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Lactobacillus GG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus GG given for six weeks two times per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo two times per day for six weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus GG</intervention_name>
    <arm_group_label>Lactobacillus GG</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Dicoflor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &lt;5,

          -  clinical symptoms of GERD

          -  treatment with proton pump inhibitors

          -  signed informed consent

        Exclusion Criteria:

          -  treatment with PPI within the last 4 weeks for at least 2 weeks

          -  administration of probiotics within 7 days prior to the study

          -  acute or chronic respiratory tract infections

          -  acute or chronic gastrointestinal tract infections

          -  neurological disorders

          -  immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katarzyna Krenke, MD</last_name>
    <phone>+48224523204</phone>
    <email>katarzynakrenke@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Piotr Dziechciarz, MD</last_name>
    <phone>+48224523292</phone>
    <email>piotrdz@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-091</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Krenlke, MD</last_name>
      <phone>+48224523204</phone>
      <email>katarzynakrenke@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Piotr Dziechciarz, MD</last_name>
      <phone>+48224523292</phone>
    </contact_backup>
    <investigator>
      <last_name>Katarzyna Krenke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piotr Dziechciarz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hania Szajewska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Horvath, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2013</study_first_submitted>
  <study_first_submitted_qc>January 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2013</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Hanna Szajewska</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

